Sarepta Therapeutics reported $904.27M in Stock for its fiscal quarter ending in June of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Amgen USD 6.22B 34M Jun/2026
BioCryst Pharmaceuticals USD 6.06M 71K Jun/2026
Biogen USD 2.38B 435.3M Jun/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Daiichi Sankyo JPY 692.38B 83.83B Mar/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Incyte USD 112.54M 3.08M Jun/2026
Insmed USD 142.38M 9.48M Jun/2026
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
Moderna USD 280M 134M Jun/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Novavax USD 10.01M 1.45M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
PTC Therapeutics USD 91.35M 15.79M Jun/2026
Regeneron Pharmaceuticals USD 3.08B 19.3M Jun/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 24.12B 620M Jun/2026
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026